Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4636129
Author(s) Stäuble, Céline K; Lampert, Markus L; Allemann, Samuel; Hatzinger, Martin; Hersberger, Kurt E; Meyer Zu Schwabedissen, Henriette E; Imboden, Christian; Mikoteit, Thorsten
Author(s) at UniBasel Hersberger, Kurt
Stäuble, Céline
Lampert, Markus Leopold
Allemann, Samuel
Hatzinger, Martin
Meyer zu Schwabedissen, Henriette
Mikoteit, Thorsten
Imboden, Christian
Year 2021
Title Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.
Journal Trials
Volume 22
Number 1
Pages / Article-Number 919
Keywords Antidepressant; Depression; Pharmaceutical care; Pharmacogenomics; Psychiatry
Mesh terms Adult; Antidepressive Agents, adverse effects; Depressive Disorder, Major, diagnosis, drug therapy, genetics; Humans; Pharmacists; Pharmacogenomic Testing; Psychotherapy; Randomized Controlled Trials as Topic
Abstract

It is known that only 50% of patients diagnosed with major depressive disorders (MDD) respond to the first-line antidepressant treatment. Accordingly, there is a need to improve response rates to reduce healthcare costs and patient suffering. One approach to increase rates of treatment response might be the integration of pharmacogenetic (PGx) testing to stratify antidepressant drug selection. The goal of PGx assessments is to identify patients who have an increased risk to experience adverse drug reactions or non-response to specific drugs. Especially for antidepressants, there is compiling evidence on PGx influencing drug exposure as well as response.; This study is an open-label, randomized controlled trial conducted in two study centers in Switzerland: (1) the Psychiatric Clinic of Solothurn and (2) the Private Clinic Wyss in Münchenbuchsee. Adult inpatients diagnosed with a unipolar moderate or severe depressive episode are recruited at clinic admission and are included in the study. If the adjustment to a new antidepressant pharmacotherapy is necessary, the participants are randomized to either Arm A (intervention group) or Arm B (control group). If no new antidepressant pharmacotherapy is introduced the participants will be followed up in an observational arm. The intervention is the service of pharmacist-guided pre-emptive PGx testing to support clinical decision making on antidepressant selection and dosing. As a comparison, in the control group, the antidepressant pharmacotherapy is selected by the treating physician according to current treatment guidelines (standard of care) without the knowledge of PGx test results and support of clinical pharmacists. The primary outcome of this study compares the response rates under antidepressant treatment after 4 weeks between intervention and control arm.; The findings from this clinical trial are expected to have a direct impact on inter-professional collaborations for the handling and use of PGx data in psychiatric practice.; ClinicalTrials.gov NCT04507555 . Registered on August 11, 2020. Swiss National Clinical Trials Portal SNCTP000004015 . Registered August 18, 2020.

ISSN/ISBN 1745-6215
Full Text on edoc
Digital Object Identifier DOI 10.1186/s13063-021-05724-5
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/34906208
   

MCSS v5.8 PRO. 0.385 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
10/08/2022